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Circulation: Heart Failure
METHODS PAPER

Novel Trial Design: CHIEF-HF
John A. Spertus , MD, MPH; Mary C. Birmingham , PharmD; Javed Butler, MD, MPH, MBA; Ildiko Lingvay, MD ;
David E. Lanfear , MD, MS; Antonio Abbate , MD; Mikhail L. Kosiborod, MD, MS; Christina Fawcett , BA, PMP;
Paul Burton , MD, PhD; C.V. Damaraju , PhD; James L. Januzzi , MD; John Whang , MD
BACKGROUND: The expense of clinical trials mandates new strategies to efficiently generate evidence and test novel therapies.
In this context, we designed a decentralized, patient-centered randomized clinical trial leveraging mobile technologies, rather
than in-person site visits, to test the efficacy of 12 weeks of canagliflozin for the treatment of heart failure, regardless of
ejection fraction or diabetes status, on the reduction of heart failure symptoms.
METHODS: One thousand nine hundred patients will be enrolled with a medical record-confirmed diagnosis of heart failure,
stratified by reduced (≤40%) or preserved (>40%) ejection fraction and randomized 1:1 to 100 mg daily of canagliflozin
or matching placebo. The primary outcome will be the 12-week change in the total symptom score of the Kansas
City Cardiomyopathy Questionnaire. Secondary outcomes will be daily step count and other scales of the Kansas City
Cardiomyopathy Questionnaire.
RESULTS: The trial is currently enrolling, even in the era of the coronavirus disease 2019 (COVID-19) pandemic.
CONCLUSIONS: CHIEF-HF (Canagliflozin: Impact on Health Status, Quality of Life and Functional Status in Heart Failure) is
deploying a novel model of conducting a decentralized, patient-centered, randomized clinical trial for a new indication for
canagliflozin to improve the symptoms of patients with heart failure. It can model a new method for more cost-effectively
testing the efficacy of treatments using mobile technologies with patient-reported outcomes as the primary clinical end
point of the trial.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04252287.
Key Words: canagliflozin ◼ cardiomyopathy ◼ COVID-19 ◼ heart failure ◼ Kansas City Cardiomyopathy Questionnaire

A

lthough cardiovascular disease remains the leading
cause of death in the United States, wide-spread
concerns have arisen about the costs, inefficiencies,
and complexities of clinical trials. These costs, as well as
barriers to regulatory approval, have dramatically attenuated the introduction of new cardiovascular treatments.1
As such, there have been calls for novel strategies to
lower the costs of clinical trials.2,3 A large component (up
to 50%) of these costs are the burden of data collection on sites, which has increased 3.6-fold from 1990
to 2010.4 In response to the growing demands to make

clinical trials more efficient, novel study designs have
been implemented, from leveraging existing registries as
the backbone of data collection5 to the use of electronic
health records to identify, enroll, randomize and follow-up
eligible patients.6
An additional significant threat to clinical trials is prolonged patient enrollment and deviations from planned
follow-up in executing clinical trials. The ongoing coronavirus disease 2019 (COVID-19) global pandemic
has proven to be a cataclysmic event for the conduct
of clinical trials, significantly disrupting patient enrollment
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Nonstandard Abbreviations and Acronyms
CHIEF-HF	Canagliflozin: Impact on Health Status, Quality of Life and Functional
Status in Heart Failure
DAPA-HF	Dapagliflozin and Prevention of
Adverse Outcomes in Heart Failure
DEFINE-HF	Dapagliflozin Effects on Biomarkers,
Symptoms and Functional Status
in Patients With HF With Reduced
Ejection Fraction
EF
ejection fraction
	
EMPEROR- Empagliflozin Outcome Trial in
Patients with Chronic Heart Failure
Reduced
and a Reduced Ejection Fraction
HF
heart failure
HFpEF
HF with preserved EF
HFrEF
HF with reduced EF
KCCQ	Kansas City Cardiomyopathy
Questionnaire
SGLT2i	sodium-glucose cotransporter 2
inhibitor

as patients and providers are all fearful of the risks of
in-person site visits. Both the US Food and Drug Administration7 and a Heart Failure (HF) Collaboratory Statement8 have highlighted the need to prioritize the safety
and well-being of HF trial participants and research team
members, even if sacrificing protocol adherence.
Against this backdrop of a call for more efficient
and cost-effective clinical trials and the need to maximize patient safety and convenience, we designed the
CHIEF-HF trial (Canagliflozin: Impact on Health Status,
Quality of Life and Functional Status in Heart Failure),
which sought to directly engage participants without inperson contact. An unplanned benefit of our trial design
was its relevance and feasibility during the COVID-19
pandemic, which had major disruptive consequences on
traditional clinical trials. This report describes the novel
methodological features of this decentralized trial.

METHODS
Evolving Role of Sodium-Glucose
Cotransporter 2 Inhibitors in HF
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), which
lower plasma glucose concentrations via increased urinary glucose excretion, are a class of medications originally developed
for the treatment of type 2 diabetes. They were also postulated
to have a potential benefit in the treatment of HF.9,10 Several
large cardiovascular outcome trials, and one large kidney outcome trial, have demonstrated robust and consistent reductions in the risk of hospitalization for HF in patients with type 2

Design of CHIEF-HF

diabetes.11,12 However, the overwhelming majority of patients in
these studies did not have a history of HF, and those that did
were not well-characterized. Therefore, although these trials
established the efficacy of SGLT2i in preventing incident HF in
high-risk patients, whether they could also treat patients with
established HF was not well established until recently.
In the DAPA-HF trial (Dapagliflozin and Prevention of
Adverse Outcomes in Heart Failure), a global randomized outcome trial of dapagliflozin versus placebo in 4744 patients with
HF and reduced ejection fraction (EF),13 patients treated with
dapagliflozin (as compared with placebo) experienced a significant 26% relative risk reduction in the primary composite
outcome of cardiovascular death or hospitalization for HF, a
benefit that emerged early and was consistent in both patients
with and without type 2 diabetes.14 The recent publication of
the EMPEROR-Reduced trial (Empagliflozin Outcome Trial in
Patients with Chronic Heart Failure and a Reduced Ejection
Fraction), which also demonstrated a significant reduction in
cardiovascular death and HF hospitalizations, further emphasized the potential benefits of SGLT2i on clinical events.15 In
addition, both DAPA-HF and EMPEROR-reduced significantly
improved HF-related symptoms, as measured by the Kansas
City Cardiomyopathy Questionnaire (KCCQ).15,16 The health
status (symptoms, physical limitations, and quality of life)
benefits of an SGLT2i were also addressed in DEFINE-HF
(Dapagliflozin Effects on Biomarkers, Symptoms and Functional
Status in Patients With HF With Reduced Ejection Fraction)—
the first randomized placebo-controlled trial of an SGLT2i
that included the KCCQ as a part of the composite primary
outcome.17 In that study, dapagliflozin significantly improved
symptoms, physical limitations, and quality of life in patients
with symptomatic HF with reduced EF after 12 weeks of treatment. Furthermore, fewer patients treated with dapagliflozin
(versus placebo) experienced a deterioration in health status,
and significantly more patients treated with dapagliflozin had
small, moderate, and large improvements in their health status.
Collectively, these data support the benefits of dapagliflozin to
improve the health status of patients with HF with reduced EF,
but none of these agents are currently indicated for the clinical
improvement in HF symptoms or for use in patients with HF
with preserved EF (HFpEF). CHIEF-HF was designed to test
the efficacy of canagliflozin on the health status outcomes of a
broad spectrum of patients with HF.

Regulatory Shifts in Clinical End Points
Marked change has occurred in the Food and Drug
Administration’s perspectives on clinical end points in HF trials
for drug approval, including endorsement that patient-reported
outcomes of reduced symptoms and improved function could
support regulatory approval.18 Moreover, the Food and Drug
Administration’s Center for Drug Evaluation and Research
recently qualified the KCCQ as a clinical outcome assessment
for drug approval and marketing.19 Collectively, the availability
of a patient-reported outcome to serve as an approvable outcome in clinical trials, coupled with the availability of mobile
technologies to collect these data, have created an unprecedented opportunity to perform clinical trials at lower costs
and with more efficiency than would otherwise be possible.
Because of this, the CHIEF-HF trial was designed with the primary outcome being the Total Symptom Score of the KCCQ to
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capture the benefits of canagliflozin over placebo on patients’
shortness of breath, fatigue, orthopnea, and edema.

Study Hypothesis
The primary hypothesis of the study is that canagliflozin is superior to placebo in improving HF symptoms within 12 weeks of
treatment, as assessed by the KCCQ Total Symptom Score.

Study Methodology
CHIEF-HF was designed to be a decentralized (ie, no face-toface visits) US study with direct engagement of patients through
a study website, electronic informed consent, direct home delivery of study medication, completion of the primary end point by
a mobile application, and a Fitbit Versa 2 (San Francisco, CA)
to monitor activity. Although clinical events were not included
as a primary end point in this 3-month trial, these will be captured through claims data or patient self-report during the
active 12-week treatment phase and the following 6 months.
Collectively, this design allowed for the elimination of in-person
site visits, a critical feature in enabling the study to launch in the
midst of the COVID-19 pandemic and for reassuring participants who might be leery of coming to a hospital or clinic.
The study was designed, in conjunction with an Executive
Steering Committee, by Janssen Scientific Affairs, LLC
(Titusville, NJ) and PRA Health Sciences (PRA, Raleigh, NC).
PRA is also leading the trial operations (with oversight by
Janssen), including the creation of the web platform and mobile
application (the primary means of data collection), randomization and drug delivery, and facilitating a virtual study coordinating center to support participant onboarding, questions,
shipping the Fitbit and supplies, confirming receipt, and drug
compliance. The organization of the study infrastructure is provided in Figure 1. The authors declare that all supporting data
are available within the article.

Funding Sources
Funding for this study has been provided by Janssen Scientific
Affairs and PRA Health Sciences.

Participant Inclusion and Exclusion Criteria and
Process for Confirming Participant Eligibility
Potential participants are screened at participating US health
systems, who all agreed to the use of a central Institutional
Review Board (Advarra, Columbia MD). The complete inclusion
and exclusion criteria are provided in the Data Supplement. In
brief, participants must be 18 years or older with a diagnosis
of HF, regardless of EF, to be eligible, irrespective of whether
they have diabetes or not. A diagnosis of HF for potential participants with a left ventricular EF of ≤40% was established by
a primary diagnosis of HF or at least 2 medical visits (including
virtual) with a diagnostic code for HF. For patients with a left
ventricular EF >40%, use of a loop diuretic or an aldosteronereceptor blocker was also required to improve diagnostic specificity. To support the mobile data collection of the KCCQ and to
provide study support, patients were required to own a smartphone compatible with the app (either a Samsung S7 Galaxy or
Apple iPhone 6 or later and the Fitbit), speak and read English,
and be willing to wear a Fitbit for 9 months.

Design of CHIEF-HF

Those with any of the following within the timeframe listed
before enrollment were excluded: currently taking an SGLT2i,
having a history of diabetic ketoacidosis or type 1 diabetes,
acute decompensated HF, advanced kidney disease (glomerular filtration rate <30 mL/min or on dialysis), a diagnosis of
recent hypotension, a history of atraumatic amputation or critical limb ischemia, planned major surgery, left ventricular assist
device implantation, known allergy to canagliflozin, or pregnant,
planning to become pregnant, or breastfeeding during the study.
To engage participants, sites are encouraged to develop a
computable phenotype for the inclusion and exclusion criteria
and to screen their electronic health record for potentially eligible participants. A range of options for contacting potentially eligible participants are available for sites to adapt, based on their
patient population and EHR capabilities. These include email,
patient portal communications through the electronic medical
record, traditional post, and phone calls. These invitations, all
approved by the Central Institutional Review Board, encourage potential participants to visit the study website, to read and
observe a video describing the study, and, if interested, to complete an initial set of screening questions confirming initial eligibility. If these criteria are met, potential participants opt-in to be
contacted and evaluated for further eligibility. Participants who
opt-in are then assessed by their respective health network for
a full eligibility review before being scheduled for a virtual eConsent call. This process reduces time invested by the sites so
they only focus on those individuals interested in study participation. Candidates passing this initial screening are then invited
to download the app in preparation for the virtual informed consent call with a member of their health network authorized to
obtain consent for CHIEF-HF and an independent observer
from the virtual study coordinating call center. Once consent
is obtained, the participant completes the KCCQ-23 to ensure
that they have an Overall Summary score of ≤80 and are sufficiently symptomatic to have the potential to improve from treatment. The use of the KCCQ as an entry criterion ensures that
patients are symptomatic and overcomes the well-documented
limitations of relying upon clinician-assigned New York Heart
Association classification.20 Once participants meet all study
criteria, they are randomized by the Virtual Investigator.

Study Protocol and Execution
CHIEF-HF is a randomized, double-blind, placebo-controlled,
decentralized, interventional, superiority study. Once participants
with confirmed HF diagnoses undergo the virtual informed consent process, provide documented consent to participate, and
are determined to have a KCCQ Overall Summary score of ≤80,
they undergo central randomization, stratified by the type of HF
(HF with reduced EF [HFrEF] and HFpEF), to either canagliflozin
100 mg or placebo for 12 weeks of drug exposure, followed by
unblinding and a 6-month observational data collection period
without study drug. Data collection throughout the study, as well
as the assessment of medication compliance and reminders for
study assessments, are being collected by the study-specific
app. Examples of selected screenshots are shown in Figure 2.
The app includes an electronic version of the KCCQ-23
that has been converted to an electronic format following the
ISPOR ePRO (International Society for Pharmacoeconomics
and Outcomes Research electronic Patient Reported Outcome)
Good Research Practices Task Force recommendations.21 The
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Figure 1. Overview of study infrastructure.
(1) At the center of the trial is the participant, who is offered participation by their provider/health network and opts in after learning more on
a central recruitment website. (2) Once their eligibility is verified by their health network, they interact with the Mobile Health Platform (mHP)
to eConsent and complete a baseline KCCQ. (3)Upon KCCQ score review for eligibility, the participant is randomized through an Interactive
Response Technology (IRT) system, which triggers direct-to-patient drug delivery. (4) The participant is also be shipped a Welcome Kit, including
the Fitbit, from the Virtual Coordinating Center, which serves as participant liaison throughout the study for technology set-up and troubleshooting,
call center support, safety reporting, and compliance monitoring. (5) All patient source data (ePROs, medication diaries) are collected via the mHP
study app and Fitbit. (6) Upon consent and randomization, a token will be applied to patients to collect medical and prescription insurance claims.
(7) All data will be integrated in and normalized within the PRA data cloud and translated into Study Data Tabulation Model (SDTM) data sets for
analysis and submission to the FDA. IRT indicates Interactive Response Technology.

app also collects participants’ global assessments of change,
their perceptions of the HF symptom severity, as well as a
participant satisfaction survey at the completion of the trial to
gain patients’ perspectives of participating in this decentralized study. It also passively collects daily Fitbit data to directly
quantify participants’ physical activity, including step count and
floors climbed. The primary outcome, the KCCQ, will be collected at baseline, weeks 2, 4, 6, and 12, and again at months 6
and 9, with the 12-week assessment (the duration of randomized, double-blind drug exposure) being the primary outcome.

The study will continue for an additional 6 months without any
protocol-mandated treatment to collect participant follow-up in
a real-world setting, including whether or not they begin openlabel SGLT2i treatment. Figure 3 provides an overview of the
study design.

Study Outcomes
The primary assessment of efficacy is the 23-item KCCQ, which
has extensive data supporting its validity, reliability, sensitivity to
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Figure 2. Sample screenshots of data collection app.
KCCQ indicates Kansas City Cardiomyopathy Questionnaire. PGIs, Patient Global Impression - Severity

clinical change, and association with other clinical events, such
as HF hospitalization and death.22–27 The primary outcome of
the CHIEF-HF study is the Total Symptom score of the KCCQ.
The Total Symptom score is comprised of 7 items, 4 assessing
symptom frequency, and 3 symptom severity or burden over the
past 2 weeks and ranges from 0 to 100 points.
Secondary outcomes include a comparison of daily step
counts acquired from the Fitbit, followed by these additional
domain scores of the KCCQ: Physical Limitation, Quality of Life,
the Clinical Summary (the average of Physical Limitation and
Total Symptom scores), and the Overall Summary (the average
of the Physical Limitation, Total Symptom, Social Functioning,
and Quality of Life domains) scores. Exploratory analyses also
include patients’ global ratings of change and symptom severity, health care resource utilization, daily floors climbed, and time
to clinical events, including time to first HF hospitalization or
death, as well as their satisfaction with the decentralized nature
of the study. Adverse event reporting will also be collected
through patient self-report.
An all-payer database (https://symphonyhealth.prahs.com/)
will be used to monitor clinical events and health care utilization, exploratory end points for this short-term trial, and to confirm patient eligibility. PRA (Symphony Health) has compiled a
database of US medical and prescription claims that cover over

300 million patients across all diagnoses, contains over 90%
coverage of prescriptions dispensed, is geographically representative and covers all payer types (Medicaid, Medicare, and
Commercial Insurers). PRA’s patient claims data include some
important patient demographics (gender, age), payer, as well
as administrative diagnosis, treatment, and procedure codes
that include date and location of service and physician name
and address. Each deidentified patient in the data is assigned
a longitudinally stable unique identifier that allows PRA to track
deidentified patients longitudinally over time and across locations of care. PRA’s encrypted anonymized patient key links
patient activities across many data sources to ensure individual
patient-level data are anonymous and protected; consistent
with US Health Insurance Portability and Accountability Act.
Despite the potential of the Symphony Health database,
there are potential limitations due to the origin of claims data
being transactional in nature. Specifically, deaths that occur
outside of the hospital may be missed, if not captured by payers. Also, while extensive, PRA’s claims data may not capture
complete activity of every enrolled patient. These caveats are
documented in the claims data analysis plan, along with the
recommendation of complementing patient activity captured
through claims data by patient-reported outcomes and site’s
electronic medical records. Importantly, the primary analyses
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Figure 3. Overview of study design.
HFpEF indicates heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; and KCCQ, Kansas City
Cardiomyopathy Questionnaire.

of changes in KCCQ scores are collected directly from the
patients as part of the trial.

Analytic Approach and Power
Analyses will be performed by intention to treat, with group allocation based upon randomization, regardless of actual use of
assigned medications. For the primary outcome, a mixed effect
model of repeated measures, adjusting for study intervention
(the primary variable of interest), stratification (HFrEF versus
HFpEF), time by study intervention, and baseline KCCQ Total
Symptom score will be performed. Although statistical significance of this comparison with least-square means will test the
primary hypothesis, the mean treatment group difference is not
as clinically interpretable as the proportion of patients who clinically improve or worsen.28 To support the clinical interpretability of the observed mean differences, the proportion of patients
who have a clinically small, but significant, moderate to large, and
large to very large change in their health status, as defined by
KCCQ changes of 5, 10, and 20 points, respectively, will be performed.23,29–31 Mortality in this short-duration trial is expected to
be low and to be comparable between groups and will be ignored
in the primary analyses of mean differences in changes in KCCQ
Total Symptom scores, but can be included in the responder
analyses by assigning them to the lowest response (greatest
deterioration) category. Should there be a >5% mortality rate and
if it is unequally distributed between treatment arms, then joint
modeling of survival and health status will be performed.32 The
key secondary end point of step counts will be compared, if the
primary analysis is significant at <5% type I error, using a 2-sided
t test. The additional secondary end points of other KCCQ scores
will be conducted in the same fashion as the primary outcome,
using the baseline score of each domain in the model.
Sample size was determined for the primary outcome by using
a 2-sample t test for continuous measures. The group mean

differences of the KCCQ Total Symptom score that have been
defined as clinically meaningful range from 3 to 5 points.29–31
Accordingly, the study was powered to detect a 3-point change
with 95% power, assuming a type 1 error of 5%, and a potential
dropout rate of 5%. This led to a target sample size of 1900
patients, randomized 1:1 to canagliflozin or placebo.

DISCUSSION
Demonstrating treatment benefit, ideally through the
conduct of randomized clinical trials, is the foundation
for advancing patient care. Yet, the cost and complexity
of current clinical trials is proving to be a great impediment.1,2,33 A report by the Eastern Research Group examining key drivers for reducing the costs of cardiovascular
phase 3 and 4 clinical trials identified lower-cost facilities
or at-home testing (up to 10%–13% cost reduction), use
of mobile technologies (up to 6%–14% cost reduction),
use of electronic health records (up to 3-8% cost reduction) and simplified protocols (up to 2%–4% reduction)
as the most important opportunities for improving the
efficiency of clinical trials.34,35 By incorporating all of
these features, CHIEF-HF has embraced multiple strategies to model a more efficient approach to generating
clinical trial evidence. It is also completely aligned with
the recommendations of the National Academy of Medicine, which recommends directly engaging health care
systems in the research enterprise.33 Although designed
before the onset of the COVID-19 pandemic, the novel
design of CHIEF-HF highlights the urgency to explore
novel approaches to generating evidence and possible
benefits of innovative study design.
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CHIEF-HF builds upon the slow evolution of novel
clinical trials. A large advance was the leveraging of ongoing clinical registries as the foundation for data collection,
such that randomization of treatments could be done with
minimal additional data collection.5 The recent publication
of the ADAPTABLE (Aspirin Dosing: A Patient-centric
Trial Assessing Benefits and Long-Term Effectiveness)
trial methodology highlighted the use of electronic health
records to identify, enroll, randomize, and follow eligible
patients.6 Although CHIEF-HF similarly uses computable
phenotypes to identify potentially eligible participants
and refer them to a website for additional information
about the trial, it also introduces a placebo-controlled
randomized design, as opposed to the open-label, dosefinding research question of ADAPTABLE. Although both
CHIEF-HF and ADAPTABLE are using claims data without adjudication to define clinical events, ADAPTABLE
required a very large trial with which to be adequately
powered for these events, whereas the primary outcome
of CHIEF-HF is patient-reported symptoms, as captured
by the extensively-validated KCCQ. In fact, the growing
acceptance of patient-reported outcomes, including the
recently qualified KCCQ, can be a harbinger of future
such studies to accelerate the conduct of more affordable
clinical trials to inform the benefits of new treatments.
There are sure to be unanticipated challenges with
CHIEF-HF. For example, current standards for Good Clinical Practice require that a disinterested party be present
to witness the informed consent process. This requires a
rather cumbersome process of coordinating a time during which a potential participant, a site investigator, and an
observer from the coordinating center can simultaneously
be available to review the consent form, address questions, and confirm the identity of the participant with dual
authentication, before obtaining an electronic signature. As
comfort grows with virtual clinical trials, this process may
be simplified by having patients view an online video and
provide an electronic signature to the electronic consent
and only arrange a video conference with the site investigator if the potential participants have additional questions.
In addition, the use of electronic activity monitors, although
not new, is still early in their evolution, and defining the
completeness of data capture and the interpretability of
results require further study. Finally, requiring a smartphone
and the ability to read and understand English can minimize the diversity of the CHIEF-HF population, although if
CHIEF-HF is successful, future studies can consider making smartphones available, providing cards for data, and
translating the platform to different languages.
An additional potential challenge with CHIEF-HF is
the growing body of evidence showing improved survival
or reduced hospitalizations with the use of SGLT2i for
patients with HF.13,15 Although some might consider it
unethical, in light of these data, to randomize patients to
placebo, the sponsor and steering committee felt that this
was reasonable based on several streams of logic. First,

Design of CHIEF-HF

the half of enrolled patients assigned to placebo would
only be exposed to inactive drug for 3 months, after which
they could openly take an SGLT2i. Second, the proactive screening process could accelerate their identification and recognition by the health care system that they
are candidates of an SGLT2i at the conclusion of the
12-week trial. Finally, and most importantly, the translation of data, even as compelling as that of DAPA-HF and
EMPEROR-Reduced,13,15 to clinical practice is notoriously
slow and inefficient. In fact, a contemporary HF registry
reported that even among patients with diabetes, <5% are
treated with SGLT2i.36 By being enrolled in CHIEF-HF, all
patients will have been identified as potential candidates
for treatment and educated about the potential benefits
of treatment so that their providers could consider adding
these medications to their HF regimen.
CHIEF-HF also provides an example of moving away
from simply enrolling a subset of patients based on their
EF. This approach was chosen because although patients
are clearly aware of their symptoms, function, and quality
of life, they are not aware of their left ventricular physiology. Focusing the primary outcome on patients’ health
status, for which the KCCQ’s validity and prognostic ability has been shown to be similar in patients with HFrEF
and HFpEF, further supports the appropriateness of combining these HF phenotypes in a patient-centered trial.23
Moreover, evidence is accumulating that the clinical benefits of SGLT2i is similar in patients with both HFrEF and
HFpEF, as seen in the recent SOLOIST-WHF (Effect of
Sotagliflozin on Cardiovascular Events in Patients With
Type 2 Diabetes Post Worsening Heart Failure) trial,
although the KCCQ data has not yet been published.37
Although the expectation is of similar benefits across the
spectrum of HF, randomization is stratified by EF and formal tests of an interaction of treatment benefit by HFrEF
and HFpEF will establish this more definitively.
In light of the growing therapeutic options for HF treatment to reduce hospitalizations and mortality,13,15,38–41
improving patients’ health status, their symptoms, function, and quality of life, may become a distinguishing feature in deciding which treatment might be started after
beta-blockade and inhibition of the renin-angiotensinaldosterone axis. Trials, like CHIEF-HF, which explicitly quantify these benefits have the ability to provide
important information for clinicians to support shared
decision-making with patients.42 Moreover, innovations in
the conduct of such trials, such as the methods exemplified in CHIEF-HF, can model ways to more efficiently
generate evidence and accelerate the evidence-base of
guidelines and care in many other therapeutic areas.43
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